What is Sanfilippo Syndrome

Sanfilippo Syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare, life-limiting genetic metabolic disorder that causes the body to lack specific enzymes needed to break down long chains of sugar molecules called heparan sulfate. This leads to toxic buildup in cells throughout the body, particularly the central nervous system, resulting in progressive cognitive decline, behavioral challenges, and physical disability.

What causes Sanfilippo Syndrome?

Sanfilippo Syndrome is an autosomal recessive disorder, meaning an affected child must inherit one faulty gene from each parent. The condition occurs because the body cannot properly break down heparan sulfate, a complex sugar molecule. As this substance accumulates in the lysosomes (the "recycling centers" of cells), it interferes with normal cellular function. This toxic buildup is especially damaging to the brain, which accounts for the severe neurological symptoms characteristic of Sanfilippo Syndrome. There are four distinct subtypes (A, B, C, and D), each caused by a mutation in a different gene responsible for producing one of the enzymes required to break down these sugar chains.

Which body systems are affected by Sanfilippo Syndrome?

Because heparan sulfate is found in connective tissues throughout the body, Sanfilippo Syndrome is a multisystemic condition. While the nervous system is most profoundly impacted, the disease affects several other areas:

• Nervous System: Causes progressive cognitive decline, severe insomnia, seizures, and movement disorders.


• Respiratory System: Frequent respiratory infections and chronic congestion.


• Skeletal and Muscular Systems: Development of joint contractures, coarse facial features, and skeletal abnormalities.


• Digestive System: Chronic gastrointestinal issues, including diarrhea or constipation, often complicate daily care.


• Lymphatic and Immune Systems: Often linked to recurrent infections and generalized systemic distress.

How common is Sanfilippo Syndrome?

Sanfilippo Syndrome is considered an ultra-rare disease. Estimates of its prevalence vary globally but are generally cited as affecting approximately 1 in 70,000 to 1 in 200,000 live births. Because it is a recessive condition, it affects males and females equally and occurs across all ethnic and geographic populations. Within the DiseaseMaps.org community, 114 people have connected to share their experiences, highlighting the importance of global collaboration for families navigating this rare diagnosis.

What differentiates Sanfilippo Syndrome from other MPS disorders?

While all mucopolysaccharidoses involve the storage of sugar molecules, Sanfilippo Syndrome is unique in its clinical presentation. Unlike other forms of MPS that may present with severe skeletal deformities or cardiac issues early on, the primary clinical impact of Sanfilippo Syndrome is neuropsychiatric. Parents often first notice signs of hyperactivity, sleep disturbances, and a plateau or regression in speech and cognitive development in early childhood (typically between ages 2 and 6). This distinct "brain-first" progression is a hallmark that separates it from other types of mucopolysaccharidosis.

Next steps

• Consult a metabolic specialist or a geneticist to discuss subtype-specific clinical trials for enzyme replacement or gene therapy.


• Connect with the DiseaseMaps.org community of 114 members to share resources and coping strategies.


• Reach out to organizations like the Team Sanfilippo Foundation for the latest updates on substrate reduction therapies and IV treatments.


• Keep a detailed log of behavioral, sleep, and respiratory changes to share with your multidisciplinary care team.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Mucopolysaccharidosis type III.


• Orphanet: Mucopolysaccharidosis type III.


• OMIM (Online Mendelian Inheritance in Man): MPS3A, MPS3B, MPS3C, MPS3D entries.


• Team Sanfilippo Foundation: Research and clinical trial updates.